BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22447520)

  • 1. Molecular genetic analysis of the hepatocyte growth factor/MET signaling pathway in pediatric medulloblastoma.
    Onvani S; Terakawa Y; Smith C; Northcott P; Taylor M; Rutka J
    Genes Chromosomes Cancer; 2012 Jul; 51(7):675-88. PubMed ID: 22447520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma.
    Kongkham PN; Northcott PA; Ra YS; Nakahara Y; Mainprize TG; Croul SE; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2008 Dec; 68(23):9945-53. PubMed ID: 19047176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
    Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
    Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
    Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-kit expression and mutational analysis in medulloblastoma.
    Chilton-Macneill S; Ho M; Hawkins C; Gassas A; Zielenska M; Baruchel S
    Pediatr Dev Pathol; 2004; 7(5):493-8. PubMed ID: 15547773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
    Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
    Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth.
    Binning MJ; Niazi T; Pedone CA; Lal B; Eberhart CG; Kim KJ; Laterra J; Fults DW
    Cancer Res; 2008 Oct; 68(19):7838-45. PubMed ID: 18829539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
    Hashimoto T; Kato M; Shimomura T; Kitamura N
    FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
    Kang JY; Dolled-Filhart M; Ocal IT; Singh B; Lin CY; Dickson RB; Rimm DL; Camp RL
    Cancer Res; 2003 Mar; 63(5):1101-5. PubMed ID: 12615728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5.
    Li Y; Fan X; Goodwin CR; Laterra J; Xia S
    BMC Cancer; 2008 Nov; 8():325. PubMed ID: 18992144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-expression of hepatocyte growth factor and c-met in epithelial odontogenic tumors.
    Poomsawat S; Punyasingh J; Vejchapipat P; Larbcharoensub N
    Acta Histochem; 2012 Jul; 114(4):400-5. PubMed ID: 21855117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
    Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
    J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth.
    Cai W; Rook SL; Jiang ZY; Takahara N; Aiello LP
    Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1885-93. PubMed ID: 10845613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration.
    Provençal M; Labbé D; Veitch R; Boivin D; Rivard GE; Sartelet H; Robitaille Y; Gingras D; Béliveau R
    Carcinogenesis; 2009 Jul; 30(7):1089-96. PubMed ID: 19359592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
    Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
    Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noncompetitive inhibition of hepatocyte growth factor-dependent Met signaling by a phage-derived peptide.
    Tam EM; Runyon ST; Santell L; Quan C; Yao X; Kirchhofer D; Skelton NJ; Lazarus RA
    J Mol Biol; 2009 Jan; 385(1):79-90. PubMed ID: 18973760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma.
    Hwang S; Kim HE; Min M; Raghunathan R; Panova IP; Munshi R; Ryu B
    J Invest Dermatol; 2015 Sep; 135(9):2283-2291. PubMed ID: 25910030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors.
    Koch A; Waha A; Tonn JC; Sörensen N; Berthold F; Wolter M; Reifenberger J; Hartmann W; Friedl W; Reifenberger G; Wiestler OD; Pietsch T
    Int J Cancer; 2001 Aug; 93(3):445-9. PubMed ID: 11433413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras pathway by binding to a multifunctional docking site of met.
    Higuchi T; Orita T; Katsuya K; Yamasaki Y; Akiyama K; Li H; Yamamoto T; Saito Y; Nakamura M
    Mol Cell Biol; 2004 Sep; 24(17):7456-68. PubMed ID: 15314156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.